Pharmafile Logo

Piramal | Healthcare

Pharma Solutions is the contract development and manufacturing (CDMO) division of Piramal | Healthcare, a part of the Piramal Enterprise. We are one of the largest custom manufacturing companies in the world that provides flexibility and scalability of operations. We have created a vast network of contract development and manufacturing facilities located in North America, Europe and Asia that offers a multitude of services that cover the entire drug-cycle, from development and commercial manufacturing to off-patent supplies of Active Pharmaceutical Ingredients (APIs) and formulations. Our network enables us to deliver benefits by strategically placing projects to take advantage of low costs, local supply chains and specific customer/ market requirements. This division features among the top 10 contract drug manufacturers in the world.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

247 Business Park, A - Wing, 6th Floor, LBS Marg, Vikhroli (West), Mumbai, Maharashtra, 400083, India
022-30956893

 Latest Content from PMHub 

Spotlight interview: 15 minutes on digital in medical communications

Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

Generating data on long-term outcomes with gene and other advanced therapies

Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

Behavioural Science in Healthcare

Personal health and wellbeing has never been more a part of the public conscious than it is now.

Why aren’t doctors using digital therapeutics?

The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these...

Four Health wins Judges Special Recognition Award PMEA 2019

We’re delighted to have won the Judge’s Special Recognition Award at the PMEA Awards 2019! Huge congratulations to the whole team for another amazing win for the GLAD I Took...

Lucid Group announces the appointment of a new Legal and Compliance manager

Lucid Group demonstrates continual investment in its infrastructure by appointing Sebastian Goodwin as its new Legal and Compliance manager.Sebastian studied politics and trained to be a lawyer before moving into...

Lucid Group Experience the Magic of Mindfulness, Meditation and Massage

This time of year can be busier than normal. Lucid Group understand the importance of taking some time out to relax and unwind. That's why yesterday, relaxation, meditation and mindfulness...

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Bedrock’s on fire for Wellbeing Week

Bedrock creates a positive working environment to enable individuals and our business to thrive.

WHITE PAPER: Patient nonadherence – the $637bn paradox

White Papers and Resources | November 25, 2019 | IGNIFI

What’s not changed for 50 years, kills 200,000 Europeans annually, costs pharma $637 billion and the NHS over £500 million a year? We’ll tell you.